Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 13/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 13/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.32 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21492249 | 1.00 | P2RX3 (0.38) | P2RX3P2RX2P2RX7FFAR1CHRNB2 | |
| SCHEMBL21503407 | 0.84 | KMT2A (0.39) | P2RX3P2RX2 | |
| SCHEMBL21491929 | 0.84 | KMT2A (0.39) | P2RX3P2RX2 | |
| SCHEMBL21492239 | 0.84 | CHRNB2 (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL21492145 | 0.81 | P2RX3 (0.38) | P2RX3P2RX2 | |
| SCHEMBL28533487 | 0.76 | PARP10 (0.35) | P2RX3P2RX2FFAR1 | |
| SCHEMBL28533490 | 0.76 | PARP10 (0.35) | P2RX3P2RX2FFAR1 | |
| SCHEMBL21492176 | 0.76 | P2RX3 (0.35) | P2RX3P2RX2P2RX7FFAR1CHRNB2 | |
| SCHEMBL21492177 | 0.76 | P2RX3 (0.35) | P2RX3P2RX2P2RX7FFAR1CHRNB2 | |
| SCHEMBL21492093 | 0.76 | CHRNB2 (0.35) | P2RX3P2RX2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-11059826-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | P2RX3 3242/4885P2RX2 3112/4885P2RX7 2326/4885 |
| US-20190322673-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | P2RX3 3242/4885P2RX2 3112/4885P2RX7 2326/4885 |
| US-11059826-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | P2RX3 3242/4885P2RX2 3112/4885P2RX7 2326/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | P2RX3 3242/4885P2RX2 3112/4885P2RX7 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.